Reduction in self-harming behaviour after zuclopenthixol decanoate

    loading  Checking for direct PDF access through Ovid

Abstract

No psychotropic drug is specifically licensed for the management of emotionally unstable borderline personality disorder. Prescribing ‘off-label’ places additional responsibilities on the prescriber and may increase liability if there are adverse effects. This case report describes a patient with borderline personality disorder who was started on zuclopenthixol decanoate with successful outcome in terms of reducing self-harming behaviour and impulsivity.

Related Topics

    loading  Loading Related Articles